Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation 

Similar presentations


Presentation on theme: "Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation "— Presentation transcript:

1 Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation  Sapna Khubchandani, George Deeb, Shannon L. Smiley, Minoo Battiwalla, Pamela Paplham, Karen Brown, Margaret Syta, Theresa Hahn, Richard Cheney, Philip L. McCarthy  Biology of Blood and Marrow Transplantation  Volume 15, Issue 7, Pages (July 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Photomicrographs of immunostains for CD3 (A, B, E, and F) and FOXP3 (C, D, G, and H) performed on FFPE tissue sections of skin biopsy specimens before (A and C) and after (B and D) treatment, and colon biopsy specimens before (E and G) and after (F and H) treatment with denileukin diftitox for posttransplantation relapsed T cell lymphoma. The skin and colon biopsy specimens exhibited histopathologic findings consistent with GVHD, with obvious decreases in cutaneous intraepidermal and colonic lamina propria CD3+ and FOXP3+ T cell frequency. (Immunoperoxidase staining; original magnification ×400.) Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation "

Similar presentations


Ads by Google